Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ELRANATAMAB-BCMM Cause C-reactive protein increased? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of C-reactive protein increased have been filed in association with ELRANATAMAB-BCMM. This represents 1.8% of all adverse event reports for ELRANATAMAB-BCMM.

10
Reports of C-reactive protein increased with ELRANATAMAB-BCMM
1.8%
of all ELRANATAMAB-BCMM reports
0
Deaths
6
Hospitalizations

How Dangerous Is C-reactive protein increased From ELRANATAMAB-BCMM?

Of the 10 reports, 6 (60.0%) required hospitalization.

Is C-reactive protein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ELRANATAMAB-BCMM. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does ELRANATAMAB-BCMM Cause?

Cytokine release syndrome (115) Death (51) Pyrexia (46) Fatigue (31) Neoplasm progression (31) Cytomegalovirus infection reactivation (29) Malignant neoplasm progression (27) Off label use (27) Immune effector cell-associated neurotoxicity syndrome (26) Infection (25)

What Other Drugs Cause C-reactive protein increased?

METHOTREXATE (5,999) ADALIMUMAB (4,579) RITUXIMAB (4,060) ETANERCEPT (3,922) TOCILIZUMAB (3,719) INFLIXIMAB (3,621) LEFLUNOMIDE (3,574) HYDROXYCHLOROQUINE (3,552) ABATACEPT (3,451) SULFASALAZINE (3,096)

Which ELRANATAMAB-BCMM Alternatives Have Lower C-reactive protein increased Risk?

ELRANATAMAB-BCMM vs ELTROMBOPAG ELRANATAMAB-BCMM vs ELTROMBOPAG OLAMINE ELRANATAMAB-BCMM vs ELUXADOLINE ELRANATAMAB-BCMM vs ELVITEGRAVIR ELRANATAMAB-BCMM vs EMAPALUMAB

Related Pages

ELRANATAMAB-BCMM Full Profile All C-reactive protein increased Reports All Drugs Causing C-reactive protein increased ELRANATAMAB-BCMM Demographics